Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

88 results about "Frontal lobe" patented technology

The frontal lobe is the largest of the four major lobes of the brain in mammals, and is located at the front of each hemisphere (in front of the parietal lobe and the temporal lobe). It is separated from the parietal lobe by a groove between tissues called the central sulcus, and from the temporal lobe by a deeper groove called the lateral sulcus (Sylvian fissure). The most anterior rounded part of the frontal lobe (though not well-defined) is known as the frontal pole, one of the three poles of the cerebrum.

Localized two-dimensional shift correlated MR spectroscopy of human brain

A two-dimensional (2D) chemical shift correlated MR spectroscopic (COSY) sequence integrated into a new volume localization technique (90°-180°-90°) for whole body MR Spectroscopy. Using the product operator formalism, a theoretical calculation of the volume localization as well as the coherence transfer efficiencies in 2D MRS is presented. A combination of different MRI transmit / receive rf coils is used. The cross peak intensities excited by the proposed 2D sequence are asymmetric with respect to the diagonal peaks. Localized COSY spectra of cerebral frontal and occipital gray / white matter regions in fifteen healthy controls are presented.
Owner:RGT UNIV OF CALIFORNIA

Highly safe intranasally administrable gene vaccines for treating alzheimer's disease

An objective of the present invention is to provide a safe and effective vaccine therapy for Alzheimer's disease. A minus strand RNA viral vector carrying amyloid gene was constructed, and administered intranasally to 24- to 25-months-old APP transgenic mice. The level of serum anti-A 42 antibody was determined and showed to be markedly higher than the control. The results of histological investigation showed that the administration of a vector of the present invention markedly reduced senile plaques in all of the frontal lobe, parietal lobe, and hippocampus. The brain A level was also markedly reduced. Furthermore, the administration of a vector of the present invention did not result in lymphocyte infiltration in the central nervous system.
Owner:DNAVEC CORP +1

Drug delivery device

The invention provides an implantable intracranial device for the site-specific delivery of a pharmaceutically active agent to a human or animal for treating a mental or neurological disorder, such as Alzheimer's disease, schizophrenia or other psychoses. The biodegradable device includes a pharmaceutically active agent for treating the disorder, polymeric nano-lipoparticles into or onto which the pharmaceutically active agent is embedded; and a polymeric matrix or scaffold incorporating the nano-lipoparticles. The nano-lipoparticles can be in the form of nano-liposhells or nano-lipobubbles. The nano-liposhells or nano-lipobubbles can include an essential fatty acid or can be conjugated to a peptide ligand which targets the device to a specific cell into which the therapeutic agent can be delivered. The device can be implanted in the sub-arachnoid space in the region of the frontal lobe of the brain.
Owner:UNIVERSITY OF THE WITWATERSRAND

Emotion regulation ability survey method based on frontal lobe EEG lateralization and ERP

The invention discloses an emotion regulation ability survey method based on frontal lobe EEG lateralization and ERP. Resting state EEG signals and task state EEG signals are acquired; filtering and down-sampling preprocessing is performed on the acquired resting state EEG signals and the task state EEG signals; power spectrum feature extraction is performed; event related potential extraction isperformed; the lateralization coefficient B and the P300 difference coefficient E are calculated; if B>0 and E>0, the emotion regulation ability is great; if B>0 or E>0, the emotion regulation abilityis common; and if B<0 and E<0, the emotion regulation ability is poor. The diagnostic error caused by subjectivity can be avoided, the objective and reliable result based on the electroencephalogramcan be provided, and a set of perfect neural survey method can be obtained through further research so that the emotion regulation ability survey accuracy can be enhanced and the considerable social benefit and economic benefit can be acquired.
Owner:TIANJIN UNIV

Automatic cardiopulmonary resuscitation device

The present invention relates to an automatic cardiopulmonary resuscitation (CPR) device which, even in the middle of performing cardiopulmonary resuscitation, can measure an electrocardiogram and oxygen saturation, can measure an electroencephalogram so as to detect in real time a brain activity indicative of the degree of blood circulation in the brain, has a defibrillation function, can use a brain activity index as a CPR signal indicating the degree of cardiopulmonary resuscitation, and can remotely monitor biometric signals at a pre-hospital stage. The present invention provides a cardiopulmonary resuscitation device comprising: an electroencephalogram detection unit for detecting an electroencephalogram signal from the frontal lobe; and a calculation processing unit for detecting a brain activity index, which is used as a CPR signal indicating the degree of cardiopulmonary resuscitation, from the electroencephalogram signal received from the electroencephalogram detection unit, wherein the calculation processing unit derives, as the brain activity index, one or more of the burst suppression ratio (BSR), the beta ratio, and the SynchFastSlow (relative synchrony of fast and slow wave, SFS). The calculation processing unit eliminates noise from the electroencephalogram signal received from the electroencephalogram detection unit, and derives the beta ratio from the electroencephalogram signal, from which noise has been eliminated, using the following formula: Beta Ratio = log[spectral power (30-47 Hz)/spectral power (11-20 Hz)] (where, spectral power (30-47 Hz) denotes the spectral power in the 30-47 Hz band of the electroencephalogram, and spectral power (11-20 Hz) denotes the spectral power in the 11-20 Hz band of the electroencephalogram).
Owner:MEDIANA +1

Non-invasive systems and methods for detecting mental impairment

ActiveUS20200029880A1ElectroencephalographyDiagnostics using lightMental impairmentNon invasive
A mental impairment detection system and non-invasive method of detecting mental impairment of a user are provided. A test (e.g., an inhibitory reflex test or a sustained attention test) is administered to the user, brain activity in a frontal lobe of the user is non-invasively detected while the test is administered to the user, and a level of mental impairment of the user is determined based on the brain activity detected in the frontal lobe of the user.
Owner:HI LLC

Validation process for ipsative assessments

This invention is a validation process for ipsative assessments. Respondents are connected to an Electroencephalograph (EEG) and some or all of the ipsative assessment questions are asked again while connected to the EEG. The EEG measuring frontal lobe responses in terms of gamma waves is compared with the assessment questions. Positive responses provide one frontal lobe response in terms of gamma waves, negative or false answers provide a different gamma response and neutral questions provide a neutral gamma response. Reading the responses then tells whether the respondent initially responded with integrity, if so the assessment is validated.
Owner:TTI SUCCESS INSIGHTS LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products